Global Information
회사소개 | 문의 | 비교리스트

VB 111(VBL Therapeutics) : 신약 인사이트와 시장 예측(2030년)

VB 111 (VBL Therapeutics)- Emerging Drug Insight and Market Forecast - 2030

리서치사 DelveInsight Business Research LLP
발행일 2020년 09월 상품 코드 959703
페이지 정보 영문 50 Pages
가격
US $ 3,250 ₩ 3,819,000 PDF (Single User License)
US $ 6,500 ₩ 7,638,000 PDF (Site License)
US $ 9,750 ₩ 11,458,000 PDF (Global License)


VB 111(VBL Therapeutics) : 신약 인사이트와 시장 예측(2030년) VB 111 (VBL Therapeutics)- Emerging Drug Insight and Market Forecast - 2030
발행일 : 2020년 09월 페이지 정보 : 영문 50 Pages

Ofranergene obadenovec(VB 111)는 고형 종양을 표적으로 하는 이중 메커니즘을 사용하는 독특한 생물학적 약제입니다. Ofranergene obadenovec는 rGBM 제II상 시험을 완료했습니다. 이것은 ofranergene obadenovec로 치료된 환자와 이후 bevacizumab 단독으로 치료된 환자, 또는 과거 bevacizumab 데이터와 비교해, 일련의 ofranergene obadenovec로 치료된 환자의 전체 생존에 통계적으로 의미가 있는 개선을 나타냈습니다.

미국, 유럽 5개국(독일, 프랑스, 이탈리아, 스페인, 영국) 및 일본 7개 주요 시장의 VB 111(VBL Therapeutics)에 대해 상세하게 설명하고(작용기서, 투여량, 합성 경로, 규제 마일스톤을 포함한 연구개발 활동 및 기타 개발 활동), SWOT 분석, 시장 경쟁사 및 기타 새로운 치료법을 포함한 향후 시장 평가를 제공합니다.

목차

제1장 의약품 개요

  • 제품 상세
  • 작용기서
  • 투약과 관리
  • 연구개발 활동
    • 임상 개발
    • 안전성과 유효성
  • 기타 개발 활동

제2장 시장 평가

  • 주요 7개국 시장 분석
  • 미국 시장
  • 독일 시장
  • 프랑스 시장
  • 이탈리아 시장
  • 스페인 시장
  • 영국 시장
  • 일본 시장

제3장 SWOT 분석

제4장 애널리스트의 견해

제5장 시장 경쟁사

제6장 기타 새로운 치료

제7장 부록

제8장 보고서 구입 옵션

KSM 20.09.16

List of Tables

  • Table 1 VB 111 (VBL THERAPEUTICS), Description
  • Table 2 VB 111 (VBL THERAPEUTICS), Clinical Trial Description
  • Table 3 VB 111 (VBL THERAPEUTICS), 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of VB 111 (VBL THERAPEUTICS)
  • Figure 2 Patent Details, VB 111 (VBL THERAPEUTICS)
  • Figure 3 VB 111 (VBL THERAPEUTICS), 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 VB 111 (VBL THERAPEUTICS), US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 VB 111 (VBL THERAPEUTICS), EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 VB 111 (VBL THERAPEUTICS), Japan Market Size from 2020 to 2030 (in Millions USD)

"VB 111 (VBL Therapeutics)- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Glioblastoma in 7 Major Markets. A detailed picture of the VB 111 (VBL THERAPEUTICS) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

Ofranergene obadenovec is a unique biologic agent that uses a dual mechanism to target solid tumors. Based on a non-integrating, non-replicating, Adeno 5 vector, ofranergene obadenovec utilizes VBL's proprietary Vascular Targeting System (VTS) to target the tumor vasculature for cancer therapy. Unlike anti-VEGF or TKIs, ofranergene obadenovec does not aim to block a specific pro-angiogenic pathway; instead, it uses an angiogenesis-specific sensor (VBL's PPE-1-3x proprietary promoter) to specifically induce cell death in angiogenic endothelial cells in the tumor milieu. This mechanism retains activity regardless of baseline tumor mutations or the identity of the pro-angiogenic factors secreted by the tumor and shows efficacy even after failure of prior treatment with other anti-angiogenics. Moreover, ofranergene obadenovec induces specific anti-tumor immune response, which is accompanied by recruitment of CD8 T-cells and apoptosis of tumor cells. Ofranergene obadenovec completed a Phase II study in rGBM, which showed a statistically significant improvement in overall survival in patients treated with ofranergene obadenovec through progression, compared to either patients treated with ofranergene obadenovec followed by bevacizumab alone, or to historical bevacizumab data.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around VB 111 (VBL Therapeutics).
  • The report contains forecasted sales for VB 111 (VBL Therapeutics) till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Glioblastoma.
  • The report also features the SWOT analysis with analyst insights and key findings of VB 111 (VBL Therapeutics).

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VB 111 (VBL Therapeutics) Analytical Perspective by DelveInsight

  • In-depth VB 111 (VBL Therapeutics) Market Assessment

This report provides a detailed market assessment of VB 111 (VBL Therapeutics) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • VB 111 (VBL Therapeutics) Clinical Assessment

The report provides the clinical trials information of VB 111 (VBL Therapeutics) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Glioblastoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence VB 111 (VBL Therapeutics) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Glioblastoma are giving market competition to VB 111 (VBL Therapeutics) and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of VB 111 (VBL Therapeutics).
  • Our in-depth analysis of the forecasted sales data of VB 111 (VBL Therapeutics) from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VB 111 (VBL Therapeutics).

Key Questions:

  • Which company is developing VB 111 (VBL Therapeutics) along with the phase of the clinical study?
  • What is the technology utilized in the development of VB 111 (VBL Therapeutics)?
  • What is the product type, route of administration and mechanism of action of VB 111 (VBL Therapeutics)?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VB 111 (VBL Therapeutics) development?
  • What are the key designations that have been granted to VB 111 (VBL Therapeutics)?
  • What is the forecasted market scenario of VB 111 (VBL Therapeutics)?
  • What is the history of VB 111 (VBL Therapeutics) and what is its future?
  • What is the forecasted sales of VB 111 (VBL Therapeutics) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to VB 111 (VBL Therapeutics)?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

Back to Top
전화 문의
F A Q